New obesity drug from Lilly delivers major weight loss
Summary
Eli Lilly announced that its new obesity drug, retatrutide, showed strong results in a late-stage clinical trial. Patients who used the drug once a week lost up to 30% of their body weight, meeting the main goals of the trial.Key Facts
- Retatrutide is an obesity drug developed by Eli Lilly.
- The drug is given as a once-weekly injection.
- In the phase 3 clinical trial, retatrutide helped patients lose up to 30% of their body weight.
- The trial met its primary goal and important secondary goals related to weight loss.
- The highest dose tested led to an average weight loss of 28.3%.
- The drug is still considered investigational, meaning it has not yet been fully approved for general use.
- The results suggest significant potential for treating obesity with this medication.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.